James S. Shannon
Independent DirectorDr. James S. Shannon, B.Sc, M.D. MRCP (UK), serves as Independent Director of Xilio Therapeutics, Inc. since June 2024. Dr. Shannon serves as Member of Scientific Advisory Board at ProQR Therapeutics N.V. since July 2020 and has been its Chairman of Advisory Board since 2020. He serves as Member of Strategic Advisory Board at Hybridize Therapeutics B.V. Dr. Shannon served as Chief Medical Officer of GlaxoSmithKline plc from May 2012 to March 2015. Dr. Shannon was responsible for matters of patient safety, general medical governance, medical ethics and integrity, medical information as well as investigations involving human subjects relating to any GSK medicine in development or on the market. Dr. Shannon is Supervisory Board Member at Leyden Laboratories B.V. Dr. Shannon had a long career serving in various senior positions with Sterling Winthrop, Sandoz and Novartis. He joined Sandoz in 1994 as Head of Drug Regulatory Affairs. He served as Global Head of Development at Novartis Pharma AG. He served as Head of Pharma Development at Novartis Consumer Health, Inc. He served as Head of Pharma Development and Head of Clinical Development & Medical Affairs at Novartis AG from 2005 until 2008. He was responsible for all of Novartis's development activities, from pre-clinical through Phase 4. He served as Senior Vice-President, Clinical Development at Sterling Winthrop Pharmaceuticals. He served as Chief Executive Officer and President of Cerimon Pharmaceuticals, Inc and was its interim Chief Executive Officer and President from January 2009 until April 2010. Dr. Shannon serves as Chairman of the Board at myTomonows (NL), Kyowa Kirin NA since July 2019 and Horizon Pharma (Ire). Dr. Shannon serves as Chairman of Supervisory Board of Impatients N.V. and has been its Member of Supervisory Board since January 11, 2016. He had been Independent Director of Horizon Therapeutics Public Limited Company (formerly known as Horizon Pharma plc) since August 03, 2017 until October 06, 2023. He has been an Independent Director of MannKind Corporation since May 21, 2015 and has been its Independent Chairman since December 9, 2020. He has been Director of Immodulon Therapeutics Limited since August 2017. He serves as Director at Leyden Labs, a private biopharma company and MyTomorrows. He serves as Independent Chairman of the Board at ProQR Therapeutics N.V. since May 2024 and served as its Chairman of the Supervisory Board since May 2024 and served as its Independent Member of Supervisory Board since June 21, 2016. He served as a Director of Biotie Therapies Corp. from April 15, 2010 to May 02, 2012, Cerimon Pharmaceuticals, Inc. since December 2008 and MannKind Corp. from February 2010 to April 2012. He served as a Member of Supervisory Board at Crucell N.V. since June 2010. He served as a Director of Xanodyne Pharmaceuticals, Inc. He served as a Director of Circassia Pharmaceuticals Plc since January 06, 2011 and Endocyte, Inc. from February 2010 to May 01, 2012. He served as a Director of Arch Therapeutics, Inc. He is a Member of Royal College of Physicians (UK). He is trained in Medicine and Cardiology. Dr. Shannon received undergraduate and postgraduate degrees in medicine at Queen's University of Belfast and holds BSc in 1977, MB, BCh, BAO in 1980 and MD in 1986.
Positions
- Company NameXilio Therapeutics, Inc.Stock CodeXLOPositionIndependent DirectorColleagues
- RRRene RussoPresident, CEO & Director
- SMSara M. BonsteinIndependent Chairman
- CFChristopher FrankenfieldCFO & COO
- KMKevin M. BrennanSenior Vice President of Finance & Accounting
- UBUli BialuchaChief Scientific Officer
- NMNathan McBrideChief Information Officer
- DJDaniel J. CurranIndependent Director
- CRCheryl Renee BlanchardIndependent Director
- Company NameProQR Therapeutics N.V.Stock CodePRQRPositionIndependent Chairman of the Board & Chairman of Scientific Advisory BoardColleagues
- DADaniel Anton de BoerFounder, CEO & Executive Director
- JSJames S. ShannonIndependent Chairman of the Board & Chairman of Scientific Advisory Board
- GPGerard PlatenburgCo-Founder, Chief Scientific Officer & Executive Director
- DHDennis HomChief Financial Officer
- SSSheila SponseleeChief People & Operations Officer
- SCSarah Cue KielyVice President of Investor Relations & Corporate Communications
- BFBart FiliusIndependent Non-Executive Director
- TMTheresa Marie HeggieIndependent Non-Executive Director
- Company NameMannKind CorporationStock CodeMNKDPositionIndependent ChairmanColleagues
- MEMichael E. CastagnaCEO & Director
- JSJames S. ShannonIndependent Chairman
- CBChristopher B. PrentissChief Financial Officer
- DBDavid B. ThomsonExecutive VP, General Counsel & Secretary
- SAStuart A. TrossChief People & Workplace Officer
- DMDominic MarascoPresident of Endocrine Business Unit
- KKKent KresaChairman Emeritus
- RJRonald J. ConsiglioIndependent Director
- ACAnthony C. HooperIndependent Director
